LABUDirexion Daily S&P Biotech Bull 3X Shares
Seeks daily investment results of 300% of the daily performance of the S&P Biotechnology Select Industry Index.
By Direxion Funds · Launched 2015
0.96%
#4,788 of 5,562 · expensive
$571M
#1,462 of 5,562 · large
+274.8%
11 years
#1,298 of 5,562 · established
Performance
Total-return NAV · USDTotal-return NAV, USD. Net of fund fees, before tax.
Classification
How Beacon categorizes this fundAsset class
EquityRegion
North americaStrategy
Leveraged
Sector
Health careIndex tracked
S&P Biotechnology Select Industry Index
What it actually holds
By weightConcentration
Top 2 holdings = 2.5% of fund✓ well diversified
Asset allocation
By sector
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsYear-on-year price swings
Worst peak-to-trough loss
Where to buy
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Seeks daily investment results of 300% of the daily performance of the S&P Biotechnology Select Industry Index.
- Strategy
- Invests primarily in financial instruments, including swap agreements and futures, to achieve 3x daily leveraged exposure to the S&P Biotechnology Select Industry Index. Concentrates investments in the biotechnology industry, rebalancing daily to maintain targeted exposure.
- Inception date
- May 28, 2015
- Fund family
- Direxion Funds
Similar ETFs
Closest matches by profileOur take
Structural notes on how this fund behaves. Read our guide on the 6 warning signs.
Leveraged ETF — not a long-term hold
This fund uses leverage to amplify daily returns (e.g. 2x or 3x of an index). Daily rebalancing creates volatility decay — over weeks and months, the fund's return drifts from the stated multiple. In trending markets with low realised volatility, leveraged index ETFs can outperform their nominal multiple; in sideways or volatile markets they bleed. Designed for short-term tactical use, not buy-and-hold.
Source: Cheng & Madhavan, 'The Dynamics of Leveraged and Inverse ETFs' (2009)
Why we flagged this: strategy=leveraged + leveraged_name_or_strategy
Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More
What's next?
You've reviewed LABU. Save it to your watchlist to track it alongside the other funds you're weighing.
Data updated on 2026-06-19